Although clear genetic connections to ALS were first established three decades ago, there has been negligible progress in the development of disease-modifying treatments for this disease. Despite tremendous unmet need, industry has often been largely baffled by a disease seemingly designed to thwart current effective drug development approaches. In the largest genetic study of ALS to date, van Rheenen and colleagues use sophisticated analyses to gain novel insights into its pathogenesis.
References
van Rheenen, W. et al. Nat. Genet. https://doi.org/10.1038/s41588-021-00973-1 (2021).
Oakes, J. A. et al. Mol. Brain 10, 5 (2017).
Kiernan, M. C. et al. Nat. Rev. Neurol. 17, 104–118 (2021).
Phillips, T. et al. Curr. Protoc. Pharmacol. 69, 5.67.1–5.67.21 (2015).
Richard, J. et al. Brain Res. 1607, 15–25 (2015).
Lebedeva, I. V. et al. Cell Death Dis. 12, 770 (2021).
Segeritz, C. J. et al. Hepatol. 69, 49–64 (2018).
Prilutsky, D. et al. Trends Mol. Med. 20, 91–104 (2014).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
S.S. and D.B.G. are both employees of Actio Biosciences, a precision medicine biotechnology company. D.B.G. is a co-founder of Praxis Precision Medicines.
Rights and permissions
About this article
Cite this article
Sahdeo, S., Goldstein, D.B. Translating amyotrophic lateral sclerosis genes into drug development leads. Nat Genet 53, 1624–1626 (2021). https://doi.org/10.1038/s41588-021-00981-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41588-021-00981-1
- Springer Nature America, Inc.
This article is cited by
-
Opinion: more mouse models and more translation needed for ALS
Molecular Neurodegeneration (2023)